home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Structural Explanation For Some Cases Of Human Acute Myeloid Leukemia

  April, 6 2001 0:30
your information resource in human molecular genetics
More than 100,000 people are diagnosed each year with leukemia, lymphoma or other blood-related cancers. Leukemia, lymphoma, Hodgkin's disease and myeloma are cancers of the body's blood forming and immune systems - the bone marrow and lymph nodes. They are considered to be related cancers because they involve the uncontrolled growth of cells with similar functions.

Despite much progress over the past several decades, most adults who develop leukemia die of the disease or complications associated with therapy, and leukemia is still the most common cause of death in children with cancer.

Most, if not all, cases of human acute myeloid leukemia (AML) are caused by mutations in or rearrangements of genes. Among the most common gene rearrangements are those involving the transcription factor complex, core-binding factor (CBF). CBF consists of two parts, one that binds directly to DNA (CBFalpha) and a second one (CBFbeta) that helps CBFalpha bind DNA. All alpha-subunits share a region that is conserved throughout evolution known as the Runt domain. This domain is responsible for both binding to DNA and interacting with the beta-subunit. Three genes in mammals encode CBFalpha and mutations in these genes are associated with human diseases.

To understand how the disease-associated mutations affect DNA binding Allan Warren of the Medical Research Council in Cambridge, UK and coworkers determined the three dimensional X-ray crystal structure of a complex between the AML1 Runt domain, CBFbeta and DNA (Nature Structural Biology, Vol. 8, No. 4, 01 Apr 2001). An important finding that comes from the structure of the complex is that most of the disease-associated mutations are in places in the Runt domain that specifically recognize the DNA. Thus, the structure explains why human disease-associated mutations in leukemogenesis and cleidocranial dysplasia lead to a loss in DNA binding since mutations at these positions are unable to interact with the DNA as well.


Dr. Allan J. Warren
MRC Laboratory of Molecular Biology
Hills Road
Cambridge CB2 2QH
Telephone: +44 1223 402 456
Fax: +44 1223 412 178
Email: ajw@mrc-lmb.cam.ac.uk

(C) Nature Structural Biology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.